drugset / Trial / NCT06277024
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
Timeline
- Start
- 2023-01-01
- Primary completion
- 2024-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | — |
| Subject | candenizumab | Unknown | — | — |
Indications
No indication recorded.